V
V. Balasubramanian
Researcher at AMET University
Publications - 26
Citations - 529
V. Balasubramanian is an academic researcher from AMET University. The author has contributed to research in topics: Dosage form & Nanomaterials. The author has an hindex of 11, co-authored 22 publications receiving 441 citations.
Papers
More filters
Journal ArticleDOI
Hydrogen fueled spark ignition engine with electronically controlled manifold injection: An experimental study
TL;DR: In this article, a single cylinder conventional spark ignition engine was converted to operate with hydrogen using the timed manifold fuel injection technique, and a solenoid operated gas injector was used to inject hydrogen into the inlet manifold at the specified time.
Journal ArticleDOI
Green synthesis and characterization of Manganese nanoparticles using natural plant extracts and its evaluation of antimicrobial activity
TL;DR: This study reported a simple, convenient and low cost method for the synthesis of manganese nanoparticles by reducingManganese acetate with the help of easily available natural products viz., lemon extract as reducing agent and turmeric curcumin as a stabilizing agent.
Patent
Dosage form containing multiple drugs
Viswanathan Srinivasan,Ralph Brown,David Brown,Himanshu Patel,Juan Carlos Menendez,V. Balasubramanian,Somphet Peter Suphasawud +6 more
TL;DR: A pharmaceutical dosage form comprising a first drug and a second drug, both of which are selected from decongestants, antitussives, expectorants, analgesics and antihistamines, is described in this paper.
Journal ArticleDOI
Oxidative stress and tumor markers in cervical cancer patients.
TL;DR: Higher levels of TSA, AST, ALT and ALP, in the circulation of cervical cancer patients may be used in the diagnosis and treatment monitoring of patients with cervical carcinoma.
Patent
Phenylepherine containing dosage form
Viswanathan Srinivasan,Ralph Brown,David Brown,Juan Carlos Menendez,V. Balasubramanian,Somphet Peter Suphasawud +5 more
TL;DR: A pharmaceutical dosage form which comprises phenylepherine or a pharmaceutically acceptable salt thereof and a second drug is defined in this paper, where the dosage form provides a plasma concentration within the therapeutic range of the second drug over a period which is coextensive with at least about 70% of the period over which the dosage forms provided a concentration within a therapeutic range.